PL3825695T3 - Biomarkery u pacjentów, którzy odpowiadają na leczenie z wykorzystaniem terapii AIT - Google Patents

Biomarkery u pacjentów, którzy odpowiadają na leczenie z wykorzystaniem terapii AIT

Info

Publication number
PL3825695T3
PL3825695T3 PL20200807.4T PL20200807T PL3825695T3 PL 3825695 T3 PL3825695 T3 PL 3825695T3 PL 20200807 T PL20200807 T PL 20200807T PL 3825695 T3 PL3825695 T3 PL 3825695T3
Authority
PL
Poland
Prior art keywords
ait
responders
biomarkers
Prior art date
Application number
PL20200807.4T
Other languages
English (en)
Inventor
Andreas Nandy
Helga Kahlert
Nadine BEREK
Melanie MERTENS-BEER
Christoph Paul Joseph WILLERS
Milena Grazyna SOKOLOWSKA
Ali Cezmi AKDIS
Original Assignee
Allergopharma GmbH & Co. KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergopharma GmbH & Co. KG filed Critical Allergopharma GmbH & Co. KG
Publication of PL3825695T3 publication Critical patent/PL3825695T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • G01N2333/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL20200807.4T 2019-11-25 2020-10-08 Biomarkery u pacjentów, którzy odpowiadają na leczenie z wykorzystaniem terapii AIT PL3825695T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19211257 2019-11-25

Publications (1)

Publication Number Publication Date
PL3825695T3 true PL3825695T3 (pl) 2024-04-22

Family

ID=68655405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20200807.4T PL3825695T3 (pl) 2019-11-25 2020-10-08 Biomarkery u pacjentów, którzy odpowiadają na leczenie z wykorzystaniem terapii AIT

Country Status (2)

Country Link
EP (1) EP3825695B1 (pl)
PL (1) PL3825695T3 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694976A2 (en) * 2011-04-06 2014-02-12 Stallergenes S.A. Biomarkers of immunotherapy efficacy
US11015221B2 (en) * 2014-10-29 2021-05-25 Stallergenes Markers of immune response
ES2826385T3 (es) * 2016-01-13 2021-05-18 Stallergenes IL-10 como biomarcador pronóstico de la sensibilidad a la inmunoterapia con alérgenos de ácaros del polvo doméstico

Also Published As

Publication number Publication date
EP3825695C0 (en) 2023-12-06
EP3825695B1 (en) 2023-12-06
EP3825695A3 (en) 2021-07-28
EP3825695A2 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
IL292727A (en) Multispecific antibodies
GB201908045D0 (en) Object analysis
SG11202102505RA (en) Analyte quantitation
GB201900677D0 (en) Biomarkers
GB201910777D0 (en) Analytical method
GB201811093D0 (en) Biomarker
GB202107813D0 (en) Biomarker
SG11202110589PA (en) Biomarkers for selinexor
EP3825695C0 (en) BIOMARKERS FOR TIA RESPONDENTS
EP4076343C0 (en) RETINOL BASED SERUM
GB2585410B (en) Analysis
GB2596002B (en) Object analysis
GB201914183D0 (en) Biomarker
GB201913846D0 (en) Biomarker
GB201913612D0 (en) Biomarker
GB201912154D0 (en) Biomarker
GB201911078D0 (en) Biomarker
GB201915228D0 (en) Biomarkers
GB201902077D0 (en) Biomarkers
GB201902070D0 (en) Biomarkers
GB202114656D0 (en) Biomarker
GB202112831D0 (en) Biomarker
GB202110365D0 (en) Biomarker
GB202014824D0 (en) Biomarker
EP4208321A4 (en) MICROTOME